Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

American Journal of Physiology - Endocrinology and Metabolism

Volumn 271, Issue 3 34-3, 1996, Pages

  Deacon, Carolyn F ^a   Pridal, Lone ^b   Klarskov, Letty ^b   Olesen, Mette ^b   Holst, Jens J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

gastrointestinal hormone; peptide degradation; region specific radioimmunoassay

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1;

AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; RADIOIMMUNOASSAY; SWINE; TISSUE METABOLISM; TISSUE SPECIFICITY;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; ORGAN SPECIFICITY; PEPTIDES; RADIOIMMUNOASSAY; SWINE;

EID: 0029797540     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bella, A. M., R. H. Erikson, and Y. S. Kim. Rat intestinal brush border membrane dipeptidyl aminopeptidase IV: kinetic properties and substrate specificity of the purified enzyme. Arch. Biochem. Biophys. 218: 156-162, 1982.
2. Buckley, D. I., and P. Lundquist. Analysis of the degradation of insulinotropin [GLP-1 (7 - 37)] in human plasma and production of degradation resistant analogs (Abstract). Regul. Pept. 40: 117, 1992.
3. Carone, F. A., and D. R. Peterson. Hydrolysis and transport of small peptides by the proximal tubules. Am. J. Physiol. 238 (Renal Fluid Electrolyte Physiol. 7): F151-F158, 1980.
4. Carone, F. A., D. R. Peterson, and G. Flouret. Renal tubular processing of small peptide hormones. J. Lab. Clin. Med. 100: 1-14, 1982.
5. Deacon, C. F., A. H. Johnsen, and J. J. Holst. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80: 952-957, 1995.
6. Deacon, C. F., M. A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J. J. Holst. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
7. Elovson, J. Biogenesis of plasma membrane glycoproteins. Purification and properties of two rat liver membrane glycoproteins. J. Biol. Chem. 255: 5807-5815, 1980.
8. Gee, N. S., M. A. Bowes, P. Buck, and A. J. Kenny. An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. Biochem. J. 228: 119-126, 1985.
9. Grandt, D., B. Sieburg, J. Sievert, M. Schimiczek, U. Becker, B. Holtmann, P. Layer, J. R. Reeve, V. E. Eysselein, H. Goebell, and M. Müller. Is GLP-1 (9 - 36)amide an endogenous antagonist at GLP-1 receptors? (Abstract) Digestion 55: 302, 1994.
10. Gutniak, M., C. Ørskov, J. J. Holst, B. Ahrén, and S. Efendic. Anti-diabetogenic effect of glucagon-like peptide-1 (7 - 36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326: 1316-1322, 1992.
11. Harling, H., and J. J. Holst. Circulating galanin: origin, metabolism and pharmacokinetics in anesthetized pigs. Am. J. Physiol. 262 (Endocrinol. Metab. 25): E52-E57, 1992.
12. Heinzel, G., R. Woloszczak, and P. Thomann. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Topfit 2.0. Stuttgart, Germany: Fischer, 1993.
13. Hendrick, G. K., A. Gjinovic, L. A. Baxter. S. Mojsov, C. B. Wollheim, J. F. Habener, and G. C. Weir. Glucagon-like peptide-1-(7 - 37) suppresses hyperglycemia in rats. Metab. Clin. Exp. 42: 1-6, 1993.
14. Holst, J. J. Gut glucagon, enterglucagon, gut glucagonlike immunoreactivity, glicentin-current status. Gastroenterology 84: 1602-1613, 1983.
15. Holst, J. J., M. Bersani, A. H. Johnsen, H. Kofod, B. Hartmann, and C. Ørskov. Proglucagon processing in porcine and human pancreas. J. Biol. Chem. 269: 18827-18833, 1994.
16. Hupe-Sodmann, K., G. P. McGregor, R. Bridenbaugh, R. Göke, B. Göke, H. Thole, B. Zimmermann, and K. Voigt. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1 (7 - 36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58: 149-156, 1995.
17. Hvidberg, A., M. T. Nielsen, J. Hilsted, C. Ørskov, and J. J. Holst. Effect of glucagon-like peptide-1 (proglucagon 78 - 107amide) on hepatic glucose production in healthy man. Metab. Clin. Exp. 43: 104-108, 1994.
18. Kenny, A. J., A. G. Booth, S. G. George, J. Ingram, D. Kershaw, E. J. Wood, and A. R. Young. Dipeptidyl peptidase IV, a kidney brush border serine peptidase. Biochem. J. 157: 169-182, 1976.
19. Kreymann, B., G. Williams, M. A. Ghatei, and S. R. Bloom. Glucagon-like peptide 1 7 - 36: a physiological incretin in man. Lancet ii: 1300-1304, 1987.
20. Lojda, Z. Studies on dipeptidyl(amino)peptidase IV (glycylproline-naphthylamidase). II. Blood vessels. Histochemistry 59: 153-166, 1979.
21. Mentlein, R., B. Gallwitz, and W. E. Schmidt. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7 - 36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214: 829-835, 1993.
22. Ørskov, C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992.
23. Ørskov, C., J. Andreasen, and J. J. Holst. All products of proglucagon are elevated in plasma from uremic patients. J. Clin. Endocrinol. Metab. 74: 379-384, 1992.
24. Ørskov, C., J. J. Holst, and O. V. Nielsen. Effect of truncated glucagon-like peptide-1 [proglucagon-(78 - 107)amide] on endocrine secretion from pig pancreas, antrum, and non-antral stomach. Endocrinology 123: 2009-2013, 1988.
25. Ørskov, C., J. J. Holst, S. Seier Poulsen, and P. Kirkegaard. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30: 874-881, 1987.
26. Ørskov, C., J. Jeppesen, S. Madsbad, and J. J. Holst. Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J. Clin. Invest. 87: 415-423, 1991.
27. Ørskov, C., L. Rabenhøj, A. Wettergren, H. Kofod, and J. J. Holst. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans. Diabetes 43: 535-539, 1994.
28. Ørskov, C., A. Wettergren, and J. J. Holst. Biological effects and metabolic rates of glucagon-like peptide-1 7 - 36 amide and glucagon-like peptide-1 7 - 37 in healthy subjects are indistinguishable. Diabetes 42: 658-661, 1993.
29. Pridal, L., S. H. Ingwersen, F. S. Larsen, J. J. Holst, K. Adelhorst, and O. Kirk. Comparison of sandwich ELISA and RIA for determination of exogenous GLP-1 (7 - 36)amide in plasma. J. Pharm. Biomed. Anal. 13: 841-850, 1995.
30. Ruiz-Grande, C., C. Alarcón, A. Alcántara, C. Castilla, J. M. López Novoa, M. L. Villanueva-Peñacarrillo, and I. Valverde. Renal catabolism of truncated glucagon-like peptide-1. Horm. Metab. Res. 25: 612-616, 1993.
31. Ruiz-Grande, C., J. Pintado, C. Alarcón, C. Castilla, I. Valverde, and J. M. López Novoa. Renal catabolism of human glucagon-like peptides 1 and 2. Can. J. Physiol. Pharmacol. 68: 1568-1573, 1990.
32. Schjoldager, B. T. G., P.-E. Mortensen, J. Christiansen, C. Ørskov, and J. J. Holst. GLP-1 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig. Dis. Sci. 35: 703-708, 1989.
33. Thorens, B., and G. Waeber. Glucagon-like peptide-1 and the control of insulin secretion in the normal state and in NIDDM. Diabetes 42: 1219-1225, 1993.
34. Wettergren, A., B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christiansen, and J. J. Holst. Truncated GLP-1 (proglucagon 78 - 107 amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38: 665-673, 1993.